INBX

Inhibrx Biosciences, Inc.

A clinical-stage biopharmaceutical company engineering biologic therapies for cancer. Its lead candidate, ozekibart, cut the risk of disease progression or death in a late-stage trial for chondrosarcoma, a rare bone cancer, and it is also studying INBRX-106 with the immunotherapy Keytruda. The name blends "inhibit" and "Rx" (prescription), and the company took its present form in 2024 when Sanofi bought one of its programs, spinning out the rest.